Ultragenyx Pharmaceutical (RARE) Competitor Comparison
We are evaluating the key criteria listed to compare Ultragenyx Pharmaceutical (RARE) against its competitors in the Biotechnology industry.
Market Capitalization
37 / 368Gross Profits
274 / 278Total Revenue
28 / 300EBITDA
326 / 337Free Cashflow
343 / 352Quick Ratio
289 / 357Earnings per Share
320 / 359Dividend yield
0 / 6Total Cash
70 / 358Performance 3 years
158 / 368Performance 5 years
118 / 368Performance 10 years
105 / 368Linearity 3 years
100 / 368Linearity 5 years
5 / 368Linearity 10 years
1 / 367Total Rank
46 / 368Dividend Rank
293 / 368Valuation Rank
30 / 368Piotroski Rank
177 / 368Muliplier Rank
103 / 368Dividend yield - RARE ranking 0 / 6
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.